Biotechnology Assets S.A. - Asset Resilience Ratio
Biotechnology Assets S.A. (BST) has an Asset Resilience Ratio of 0.34% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Biotechnology Assets S.A. balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2024)
This chart shows how Biotechnology Assets S.A.'s Asset Resilience Ratio has changed over time. See Biotechnology Assets S.A. free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Biotechnology Assets S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Biotechnology Assets S.A. (BST) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €46.18K | 0.34% |
| Total Liquid Assets | €46.18K | 0.34% |
Asset Resilience Insights
- Limited Liquidity: Biotechnology Assets S.A. maintains only 0.34% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Biotechnology Assets S.A. Industry Peers by Asset Resilience Ratio
Compare Biotechnology Assets S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 0.91% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Larimar Therapeutics Inc
NASDAQ:LRMR |
Biotechnology | 38.46% |
|
PharmaEngine
TWO:4162 |
Biotechnology | 62.91% |
Annual Asset Resilience Ratio for Biotechnology Assets S.A. (2010–2024)
The table below shows the annual Asset Resilience Ratio data for Biotechnology Assets S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.32% | €46.62K ≈ $54.50K |
€14.78 Million ≈ $17.28 Million |
+0.04pp |
| 2023-12-31 | 0.27% | €44.90K ≈ $52.50K |
€16.61 Million ≈ $19.42 Million |
-0.20pp |
| 2022-12-31 | 0.47% | €86.70K ≈ $101.37K |
€18.47 Million ≈ $21.60 Million |
+0.34pp |
| 2021-12-31 | 0.12% | €24.79K ≈ $28.98K |
€19.88 Million ≈ $23.24 Million |
0.00pp |
| 2020-12-31 | 0.13% | €25.51K ≈ $29.82K |
€20.21 Million ≈ $23.63 Million |
-1.11pp |
| 2019-12-31 | 1.23% | €1.14 Million ≈ $1.33 Million |
€92.67 Million ≈ $108.34 Million |
-0.22pp |
| 2018-12-31 | 1.45% | €1.15 Million ≈ $1.34 Million |
€79.24 Million ≈ $92.64 Million |
-3.57pp |
| 2017-12-31 | 5.02% | €882.53K ≈ $1.03 Million |
€17.58 Million ≈ $20.56 Million |
-0.87pp |
| 2016-12-31 | 5.89% | €940.06K ≈ $1.10 Million |
€15.97 Million ≈ $18.67 Million |
-0.13pp |
| 2015-12-31 | 6.02% | €890.19K ≈ $1.04 Million |
€14.80 Million ≈ $17.30 Million |
-0.07pp |
| 2014-12-31 | 6.08% | €893.01K ≈ $1.04 Million |
€14.68 Million ≈ $17.17 Million |
+4.22pp |
| 2013-12-31 | 1.86% | €172.12K ≈ $201.23K |
€9.25 Million ≈ $10.81 Million |
-3.87pp |
| 2012-12-31 | 5.73% | €436.07K ≈ $509.81K |
€7.61 Million ≈ $8.90 Million |
+4.20pp |
| 2011-12-31 | 1.53% | €111.46K ≈ $130.31K |
€7.29 Million ≈ $8.53 Million |
-12.36pp |
| 2010-12-31 | 13.89% | €698.48K ≈ $816.60K |
€5.03 Million ≈ $5.88 Million |
-- |
About Biotechnology Assets S.A.
Biotechnology Assets, S.A. develops and markets biotechnological assets for applications in the biopharmaceutical, agrochemical, cosmetic, veterinary, and chemical industries in Spain and internationally. It offers SPLITTERA, a protein engineering tool that allows the conjugation of proteins through the formation of new peptide bonds; universal switchable split-chimeric antigen receptor (CAR); VA… Read more